Consensus on core domains for hand eczema trials: Signs, symptoms, control and quality of life

• Published in: Journal of the European Academy of Dermatology and Venereology Vol. 39; no. 9; pp. 1588 - 1599
• Main Authors: Rönsch, Henriette, Drewitz, Karl Philipp, Atwater, Amber Reck, Becker, Detlef, Bentz, Philipp, Brans, Richard, Chong, Tricia, Dickel, Heinrich, Elsner, Peter, Giménez‐Arnau, Ana M., Guarneri, Fabrizio, Guzmán Perera, María Graciela, Ibrahim, Sarah, Koumaki, Dimitra, Koelbel, Jamie, Larese Filon, Francesca, Ljubojević Hadžavdić, Suzana, Loman, Laura, Matura, Mihaly, Molin, Sonja, Ofenloch, Robert, Piontek, Katharina, Spiewak, Radoslaw, Strunk, Anne, Reeder, Margo, Reissig, David, Rustemeyer, Thomas, Schuttelaar, Marie‐Louise, Simon, Dagmar, Sloot, Manon, Steiner, Markus F. C., Tongalaza, Saïda, Valiukevičienė, Skaidra, Waitek, Maurice, Weisshaar, Elke, Wöhrl, Stefan, Wolff, Doreen, Bauer, Andrea, Apfelbacher, Christian
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.09.2025
• Subjects: Clinical Trials as Topic; Consensus; Delphi Technique; Eczema - diagnosis; Eczema - psychology; Eczema - therapy; Female; Hand Dermatoses - diagnosis; Hand Dermatoses - psychology; Hand Dermatoses - therapy; Humans; Male; Original; Original and Systematic Review; Quality of Life
• ISSN: 0926-9959; 1468-3083; 1468-3083
• DOI: 10.1111/jdv.20671

Background Hand eczema (HE) is a common and complex skin disease. A uniform set of core outcomes and related measures for use in clinical trials is lacking, making it difficult to compare results across HE studies. Objective To reach consensus on a set of core domains and subdomains that should be measured in future therapeutic HE trials. Methods In 2024, we conducted a two‐round online Delphi (eDelphi) survey among international HE experts, including physicians, patients and their relatives, researchers and industry representatives. A domain/subdomain was included in the core set when ≥80% of participants rated is as ‘critically important’; 50% agreement or less resulted in its exclusion. Results from 50% to 80% were deemed controversial and subject for further discussion. During a hybrid consensus meeting, the stakeholders reviewed, completed and, if necessary, revised the preliminary eDelphi consensus. Results In the first and second round of the eDelphi, 208 and 134 persons, respectively, participated. Forty participants from 18 countries attended the consensus meeting. Consensus was reached to include the core domains ‘signs of HE’ (with five core subdomains), ‘symptoms of HE’ (two subdomains), ‘HE‐related quality of life’ (four subdomains) and ‘HE control over time’ (four subdomains). The subdomains ‘desquamation/scaling’ and ‘emotional impact/mental health’ remained controversial. Consensus was reached that the domains ‘skin barrier function’ and ‘patient‐reported treatment experience’ and 28 subdomains should not be part of the core outcome set. Conclusions To produce comparable and meaningful results, future trials evaluating the effectiveness of HE treatments should measure signs and symptoms of HE, HE‐related quality of life and HE control over time as core outcome domains. The next step of the HE core outcome set initiative (HECOS) is to identify appropriate measurement instruments. A core domain set for hand eczema was developed in an international consensus study with an online Delphi survey and a consensus meeting. Signs and symptoms of hand eczema, related quality of life and control over time should be measured in all future hand eczema therapeutic trials.